Cancer Gene Therapy Market Benefits, Opportunities and Future Investments Forecast To 2024

Globally, rising cancer prevalence will increase demand for gene therapy as the effective personalized treatment choice. According to WHO, cancer incidence is projected to rise by 50% to reach 15 million by the end of this decade.

Delaware, Selbyville - June 13, 2019 /MarketersMedia/ —

Cancer Gene Therapy Market size is expected to exceed USD 4.3 billion by 2024; as per a new research report by Global Market Insights, Inc.

Globally, rising cancer prevalence will increase demand for gene therapy as the effective personalized treatment choice. According to WHO, cancer incidence is projected to rise by 50% to reach 15 million by the end of this decade. This alarming increase in number of patients necessitates this as a potential treatment approach addressing the growing global burden of the disease.

Retroviral vector-mediated gene transfer dominated the development by enabling the conversion of single stranded RNA into a double stranded DNA molecule, which steadily integrates into the target cell genome. These vectors are used to permanently modify the host cell nuclear genome and will register a robust growth of over 20%.

Request a sample of this premium report titled at https://www.marketstudyreport.com/request-a-sample/467801/?utm_source=MM-VHS

Growing number of clinical trials and availability of wide range of genes and vectors used in these trials will enable emergence of new treatment modalities to help make cancer a manageable disease. By the end of 2012, the number of clinical trials crossed 1,800 worldwide.

Adenoviral vector remains as the most common oncology application due to its competent nuclear mechanism and low pathogenicity. It is widely used in replacement approaches, suicide and gene-based immunotherapy, and syndicate with chemotherapy and is anticipated to grow at 20% CAGR.

Increased adoption of emerging genomic technologies such as NGS and high density micro array coupled with favorable government initiatives will fuel global cancer gene therapy market size. For instance, CDC supports nationwide screening programs for control of breast, cervical and colorectal cancer among low-income women with little or no health insurance. However, high cost of development lack of reimbursement and regulatory processes will restrain industry growth.

U.S. led the industry owing to increased R&D funding and other government initiatives. Growing number of biotech companies are engaging in R&D and clinical trials of gene therapy products. Increased demand for DNA vaccines and increasing interest of venture capitalists to invest in commercialization of gene therapies will trigger industry expansion.

China cancer gene therapy market size attributed to over 35% APAC revenue in 2015. With the launch of Gendicine and increasing healthcare expenditure and robust R&D facilities will enable industry growth.

Key insights from the report include:

U.S. cancer gene therapy market share accounted for over 95% regional revenue in 2015, with market size of USD 235 million and a forecast to grow at 20.9% CAGR.

Request a discount on standard prices of this premium report titled at https://www.marketstudyreport.com/check-for-discount/467801/?utm_source=MM-VHS

UK was over USD 92.0 million in 2015, and will grow at 20.8% CAGR owing to increasing incidence of cancer and adoption of advanced treatment methods.
China market size was valued at USD 99.6 million in 2015 and growth expectations of 21% CAGR over the forecast years.

Key players include SiBiono, Altor Bioscience Corporation, Shanghai Sunway Biotech company limited, Amgen, BioCancell, OncoGeneX, Aduro Biotech, GlobeImmune, Inc., New Link Genetics., ZioPharm Oncology, MolMed, GENELUX, Gradalis, MultiVir.
The industry is highly fragmented and is dominated by several small biotech firms collectively accounting for over 80% of cancer gene therapy market pipeline. Major growth strategies adopted by these small firms include, technology transfer, licensing and commercialization deals, strategic collaborations and mergers and acquisitions to retain their industry position.

Report Content
Chapter 1. Methodology and Scope
1.1. Research Methodology
1.1.1. Initial data exploration
1.1.2. Statistical modeling and forecast
1.1.3. Industry insights and validation
1.1.4. Research scope & assumptions
1.2. Data Sources
Chapter 2. Executive Summary
2.1. Cancer genetics industry 360 degree synopsis, 2012 - 2024
2.1.1. Business trends
2.1.2. Regional trends
2.1.3. Application trends
Chapter 3. Cancer Gene Therapy Industry Insights
3.1. Industry segmentation
3.2. IIndustry Size and forecast, 2012 - 2024
3.3. Industry Impact forces
3.3.1. Growth drivers
3.3.1.1. Technological advancements
3.3.1.2. Increased adoption of nanotechnology
3.3.1.3. Favorable government regulations
3.3.2. Industry pitfalls & challenges
3.3.2.1. High cost of cancer genetherapy
3.4. Growth potential analysis
3.5. Porter's analysis
3.6. Key opportunities prioritized, 2015
3.7. PESTEL analysis
3.8. Regulatory Landscape
3.8.1. U.S.
3.8.2. EU
3.8.3. China
3.9. Scientific and Ethical issues in Gene Therapy
3.10. Competitive landscape, 2015
3.11. Pipeline Analysis by cancer type
3.11.1. Head and Neck Cancer Pipeline Analysis
3.11.2. Breast Cancer Pipeline Analysis
3.11.3. Gastro Intestinal Cancer Pipeline Analysis
3.11.4. Gentiourinary Cancer Pipeline Analysis
3.11.5. Gynecological Cancer Pipeline Analysis
3.11.6. Haemotological Cancer Pipeline Analysis
3.11.7. Neurologic Cancer Pipeline Analysis
3.11.8. Respiratory Cancer Pipeline Analysis
3.11.9. Skin Cancer Pipeline Analysis
Chapter 4. Cancer Gene Therapy Insights
4.1. Cancer gene therapy market share by therapy, 2015 & 2024
4.2. Gene Induced Immunotherapy
4.2.1. Market estimates and forecast, 2012-2024 (USD Million)
4.2.2. Delivery of cytokine gene
4.2.2.1. Market estimates and forecast, 2012-2024 (USD Million)
4.2.3. Delivery of tumor antigen gene
4.2.3.1. Market estimates and forecast, 2012-2024 (USD Million)
4.3. Oncolytic Virotherapy
4.3.1. Market estimates and forecast, 2012-2024 (USD Million)
4.3.2. Adenoviruses
4.3.2.1. Market estimates and forecast, 2012-2024 (USD Million)
4.3.3. Lentiviruses
4.3.3.1. Market estimates and forecast, 2012-2024 (USD Million)
4.3.4. Retrovirus
4.3.4.1. Market estimates and forecast, 2012-2024 (USD Million)
4.3.5. Adeno Associated Virus
4.3.5.1. Market estimates and forecast, 2012-2024 (USD Million)
4.3.6. Herpes Simplex Virus
4.3.6.1. Market estimates and forecast, 2012-2024 (USD Million)
4.3.7. Alphavirus
4.3.7.1. Market estimates and forecast, 2012-2024 (USD Million)
4.3.8. Vaccinia Virus
4.3.8.1. Market estimates and forecast, 2012-2024 (USD Million)
4.3.9. Simian Virus
4.3.9.1. Market estimates and forecast, 2012-2024 (USD Million)
4.3.10. Others
4.3.10.1. Market estimates and forecast, 2012-2024 (USD Million)
4.4. Gene transfer/ Gene replacement
4.4.1. Market estimates and forecast, 2012-2024 (USD Million)
4.4.2. Naked/Plasmid Vectors
4.4.2.1. Market estimates and forecast, 2012-2024 (USD Million)
4.4.3. Electroporation
4.4.3.1. Market estimates and forecast, 2012-2024 (USD Million)
4.4.4. Sonoportion
4.4.4.1. Market estimates and forecast, 2012-2024 (USD Million)
4.4.5. Magnetofection
4.4.5.1. Market estimates and forecast, 2012-2024 (USD Million)
4.4.6. Gene Gun
4.4.6.1. Market estimates and forecast, 2012-2024 (USD Million)

Complete report titled at https://www.marketstudyreport.com/reports/cancer-gene-therapy-market

About Us:

Marketstudyreport.com allows you to manage and control all corporate research purchases to consolidate billing and vendor management. You can eliminate duplicate purchases and customize your content and license management.

Contact Info:
Name: Arun Hegde
Email: Send Email
Organization: Market Study Report
Address: 4 North Main Street, Selbyville, Delaware 19975 USA
Phone: 1-302-273-0910
Website: https://www.marketstudyreport.com/

Source URL: https://marketersmedia.com/cancer-gene-therapy-market-benefits-opportunities-and-future-investments-forecast-to-2024/524003

Source: MarketersMedia

Release ID: 524003

More Press Releases

Stocks edge higher; S&P 500 heads for another week of gains

Sep 23, 2019

NEW YORK — U.S. stocks edged higher in early trading on Friday as most sectors of the market posted small gains. The S&P 500 rose 0.3% to 3,014 and is within 12 points of all-time high. The index is headed for a fourth straight weekly gain, even after some volatility during the week caused by volatile oil prices and the Federal Reserve's latest interest rate cut. Health care and technology stocks are leading the gains. Big pharmaceutical companies, including Pfizer and Merck were among the biggest winners. Tech giant Apple also made solid gains. Bank stocks rose as bond yields...

Japan central bank stands pat after Fed rate cut

Sep 23, 2019

TOKYO — Japan's central bank opted Thursday to keep its monetary policy unchanged despite the growing signs of trouble that prompted the Federal Reserve to cut its benchmark rate. The Bank of Japan said in its policy statement that exports, industrial output and business sentiment had been affected by the slowdown in overseas markets. The China-U.S. tariff war has pummeled Japan's exports. But the BOJ said strong corporate profits were supporting business investment. The Federal Reserve reduced its key short-term rate — which influences many consumer and business loans — by a quarter-point to a range of 1.75%-2% on Wednesday....

Oil price drops on hopes for quick recovery of Saudi output

Sep 23, 2019

LONDON — The price of oil is falling back further after the Saudi government said half of production that was knocked out by an attack over the weekend had already had been restored. Benchmark U.S. crude was down 42 cents to $58.92 per barrel in electronic trading Wednesday. The contract fell $3.56 on Tuesday. Brent crude, the international benchmark, fell 27 cents to $64.28 per barrel in London, having dropped $4.47 the previous session. The attack on oil producer Saudi Aramco's processing facility in Abqaiq saw crude surge more than 14% on Monday, about as much as it did when...

Stocks mixed, oil down as markets await news on Saudi plant

Sep 23, 2019

BANGKOK — World shares were mixed on Tuesday and oil prices eased back pending updates on restoring output at a Saudi Aramco oil processing plant damaged by an attack over the weekend. Chinese benchmarks led declines in Asia after the credit ratings agency Moody's downgraded Hong Kong, citing its recent political turmoil. Germany's DAX lost 0.2% to 12,362 after the ZEW index showed a drop in investor confidence in current economic conditions, pointing to the possibility of a brief recession, but sees a pick-up later in the year. The CAC 40 in Paris added 0.1% to 5,607 and the FTSE...

Markets Right Now: Stocks fall as oil prices spike

Sep 23, 2019

NEW YORK — The latest on developments in financial markets (all times local): 4 p.m. Stocks are closing lower Monday as a spike in oil prices raises fresh worries about the strength of the global economy. The U.S. and international benchmarks for crude oil each rose more than 14% after a weekend attack on oil facilities in Saudi Arabia. Shares of oil producers jumped, with Marathon Oil gaining 11.5%. Companies in fuel-dependent industries fell. American Airlines dropped 7.3% and Carnival Corp. slipped 3.2%. The Dow Jones industrials fell 142 points, or 0.5%, to 27,076, breaking an eight-day win streak. The...

Subscribe to our newsletter!

Your Name

Your Email Address